Safety and Tolerability of Repeat Courses of IM Alefacept
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
Previous Biogen studies have provided experience with the tolerability, immunogenicity, and
efficacy of a single and multiple 12-week courses of therapy of alefacept. At this stage,
experience in larger studies, as well as the FDA-approved labeling, is confined to treatment
courses of 12 weeks. The purpose of the present study is to offer an extended course of
therapy with alefacept.